Is INDV or IONS more undervalued in 2026?

CirclFi compares Indivior Pharmaceuticals, Inc. (INDV) and Ionis Pharmaceuticals, Inc. (IONS) using 13 institutional-grade valuation models. INDV has a Quality of Company score of 5.9/10 while IONS scores 3.6/10.

Which is a better buy — INDV or IONS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do INDV and IONS valuations compare?

INDV at $36.02 and IONS at $76.50 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

INDV vs IONS Valuation Comparison 2026 — Intrinsic Value Analysis

INDV

Pharmaceutical Preparations

Indivior Pharmaceuticals, Inc.

Quality

5.9

out of 10

Value Trap

SAFE

Price

$36.02

Last close

Models

12/13

Active

IONS

Pharmaceutical Preparations

Ionis Pharmaceuticals, Inc.

Quality

3.6

out of 10

Value Trap

SAFE

Price

$76.50

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	INDV Fair Value	INDV Upside	IONS Fair Value	IONS Upside
Bayesian DCF	Intrinsic	$8.35	-76.8%	$25.59	-66.6%
Earnings Power Value	Intrinsic	$18.45	-48.8%	$36.24	-50.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for INDV vs IONS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INDV vs IONS — Which Stock Is More Undervalued?

INDV scores higher with a 5.9/10 quality rating vs IONS's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Indivior Pharmaceuticals, Inc. (INDV) and Ionis Pharmaceuticals, Inc. (IONS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INDV currently trades at $36.02 with a QOC of 5.9/10, while IONS trades at $76.50 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).